Transforming Growth Factor beta2
"Transforming Growth Factor beta2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A TGF-beta subtype that was originally identified as a GLIOBLASTOMA-derived factor which inhibits the antigen-dependent growth of both helper and CYTOTOXIC T LYMPHOCYTES. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta2 and TGF-beta2 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor.
| Descriptor ID |
D053781
|
| MeSH Number(s) |
D12.644.276.374.687.200 D12.644.276.954.775.200 D12.776.467.374.687.200 D12.776.467.942.775.200 D23.529.374.687.200 D23.529.942.775.200
|
| Concept/Terms |
Transforming Growth Factor beta2- Transforming Growth Factor beta2
- Glioblastoma-Derived T-Cell Suppressor Factor
- Glioblastoma Derived T Cell Suppressor Factor
- Cartilage-Inducing Factor-B
- Cartilage Inducing Factor B
- Polyergin
- TGF-beta2
- TGF-beta-2
- BSC-1 Cell Growth Inhibitor
- BSC 1 Cell Growth Inhibitor
- Suppressor Factor, T-Cell, Glioblastoma-Derived
|
Below are MeSH descriptors whose meaning is more general than "Transforming Growth Factor beta2".
Below are MeSH descriptors whose meaning is more specific than "Transforming Growth Factor beta2".
This graph shows the total number of publications written about "Transforming Growth Factor beta2" by people in this website by year, and whether "Transforming Growth Factor beta2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Transforming Growth Factor beta2" by people in Profiles.
-
Protective Effects of Activated Myofibroblasts in the Pressure-Overloaded Myocardium Are Mediated Through Smad-Dependent Activation of a Matrix-Preserving Program. Circ Res. 2019 04 12; 124(8):1214-1227.
-
Aldose reductase modulates acute activation of mesenchymal markers via the ?-catenin pathway during cardiac ischemia-reperfusion. PLoS One. 2017; 12(11):e0188981.
-
Loss of the transforming growth factor-? effector ?2-Spectrin promotes genomic instability. Hepatology. 2017 02; 65(2):678-693.
-
Biomarkers and mortality in severe Chagas cardiomyopathy. Glob Heart. 2015 Sep; 10(3):173-80.
-
HOXB7 promotes malignant progression by activating the TGF? signaling pathway. Cancer Res. 2015 Feb 15; 75(4):709-19.
-
Loeys-Dietz syndrome type 4, caused by chromothripsis, involving the TGFB2 gene. Gene. 2014 Mar 15; 538(1):69-73.
-
Snail cooperates with KrasG12D to promote pancreatic fibrosis. Mol Cancer Res. 2013 Sep; 11(9):1078-87.
-
Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1a-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013 Jun; 73(9):970-8.
-
Effect of TGF-? on ocular surface epithelial cells. Exp Eye Res. 2013 Feb; 107:88-100.
-
HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest. 2012 Oct; 122(10):3603-17.